Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices.

Catarino R, Petignat P, Dongui G, Vassilakos P.

World J Clin Oncol. 2015 Dec 10;6(6):281-90. doi: 10.5306/wjco.v6.i6.281. Review.

2.

Performance of alternative strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review and meta-analysis of diagnostic test accuracy studies.

Fokom-Domgue J, Combescure C, Fokom-Defo V, Tebeu PM, Vassilakos P, Kengne AP, Petignat P.

BMJ. 2015 Jul 3;351:h3084. doi: 10.1136/bmj.h3084. Review.

3.

Low resource screening method of pre-cancerous lesions and its reversal by Triphala in teen-age Indian population.

Deshpande A, Tandon S, Deshpande N.

Ayu. 2014 Apr;35(2):160-7. doi: 10.4103/0974-8520.146233.

4.

Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.

Kiatpongsan S, Kim JJ.

PLoS One. 2014 Sep 8;9(9):e106836. doi: 10.1371/journal.pone.0106836. eCollection 2014.

5.

Performance of a low cost magnifying device, Magnivisualizer, versus colposcope for detection of pre-cancer and cancerous lesions of uterine cervix.

Singh V, Parashari A, Gupta S, Sodhani P, Sehgal A.

J Gynecol Oncol. 2014 Oct;25(4):282-6. doi: 10.3802/jgo.2014.25.4.282. Epub 2014 Jun 18.

6.

Accuracy of visual inspection with acetic acid to detect cervical cancer precursors among HIV-infected women in Kenya.

Huchko MJ, Sneden J, Sawaya G, Smith-McCune K, Maloba M, Abdulrahim N, Bukusi EA, Cohen CR.

Int J Cancer. 2015 Jan 15;136(2):392-8. doi: 10.1002/ijc.28996. Epub 2014 Jun 10.

7.

Distribution of Human Papillomavirus Genotypes among HIV-Positive and HIV-Negative Women in Cape Town, South Africa.

McDonald AC, Tergas AI, Kuhn L, Denny L, Wright TC Jr.

Front Oncol. 2014 Mar 14;4:48. doi: 10.3389/fonc.2014.00048. eCollection 2014.

8.

A population-based study of visual inspection with acetic acid (VIA) for cervical screening in rural Nigeria.

Ajenifuja KO, Gage JC, Adepiti AC, Wentzensen N, Eklund C, Reilly M, Hutchinson M, Burk RD, Schiffman M.

Int J Gynecol Cancer. 2013 Mar;23(3):507-12. doi: 10.1097/IGC.0b013e318280f395.

9.

Comparative study of effectiveness of Pap smear versus visual inspection with acetic acid and visual inspection with Lugol's iodine for mass screening of premalignant and malignant lesion of cervix.

Consul S, Agrawal A, Sharma H, Bansal A, Gutch M, Jain N.

Indian J Med Paediatr Oncol. 2012 Jul;33(3):161-5. doi: 10.4103/0971-5851.103143.

10.

Visual inspection of cervix with Lugol's iodine for early detection of premalignant & malignant lesions of cervix.

Ghosh P, Gandhi G, Kochhar PK, Zutshi V, Batra S.

Indian J Med Res. 2012 Aug;136(2):265-71.

11.

Single-visit approach of cervical cancer screening: see and treat in Indonesia.

Vet JN, Kooijman JL, Henderson FC, Aziz FM, Purwoto G, Susanto H, Surya IG, Budiningsih S, Cornain S, Fleuren GJ, Trimbos JB, Peters AA.

Br J Cancer. 2012 Aug 21;107(5):772-7. doi: 10.1038/bjc.2012.334. Epub 2012 Jul 31.

12.

Visual inspection with acetic acid for detection of high grade lesion in atypical squamous cells and low grade squamous intraepithelial lesions from cervical Pap smear.

Pothisuwan M, Pataradool K, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Thawaramorn T.

J Gynecol Oncol. 2011 Sep;22(3):145-51. doi: 10.3802/jgo.2011.22.3.145. Epub 2011 Sep 28.

13.

Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy.

Gravitt PE, Belinson JL, Salmeron J, Shah KV.

Int J Cancer. 2011 Aug 1;129(3):517-27. doi: 10.1002/ijc.25974. Review.

14.

Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India.

Gravitt PE, Paul P, Katki HA, Vendantham H, Ramakrishna G, Sudula M, Kalpana B, Ronnett BM, Vijayaraghavan K, Shah KV; CATCH Study Team..

PLoS One. 2010 Oct 28;5(10):e13711. doi: 10.1371/journal.pone.0013711.

15.

eC3--a modern telecommunications matrix for cervical cancer prevention in Zambia.

Parham GP, Mwanahamuntu MH, Pfaendler KS, Sahasrabuddhe VV, Myung D, Mkumba G, Kapambwe S, Mwanza B, Chibwesha C, Hicks ML, Stringer JS.

J Low Genit Tract Dis. 2010 Jul;14(3):167-73. doi: 10.1097/LGT.0b013e3181cd6d5e.

16.

A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo.

Hovland S, Arbyn M, Lie AK, Ryd W, Borge B, Berle EJ, Skomedal H, Kadima TM, Kyembwa L, Billay EM, Mukwege D, Chirimwami RB, Mvula TM, Snijders PJ, Meijer CJ, Karlsen F.

Br J Cancer. 2010 Mar 16;102(6):957-65. doi: 10.1038/sj.bjc.6605594. Epub 2010 Mar 2.

17.

Cervical cancer screening among college students in ghana: knowledge and health beliefs.

Abotchie PN, Shokar NK.

Int J Gynecol Cancer. 2009 Apr;19(3):412-6. doi: 10.1111/IGC.0b013e3181a1d6de.

18.

Implementation of 'see-and-treat' cervical cancer prevention services linked to HIV care in Zambia.

Mwanahamuntu MH, Sahasrabuddhe VV, Pfaendler KS, Mudenda V, Hicks ML, Vermund SH, Stringer JS, Parham GP.

AIDS. 2009 Mar 27;23(6):N1-5. doi: 10.1097/QAD.0b013e3283236e11. No abstract available.

19.

Bayesian estimation of performance measures of cervical cancer screening tests in the presence of covariates and absence of a gold standard.

Martinez EZ, Louzada-Neto F, Derchain SF, Achcar JA, Gontijo RC, Sarian LO, Syrjänen KJ.

Cancer Inform. 2008;6:33-46. Epub 2008 Feb 14.

20.

Optical imaging for cervical cancer detection: solutions for a continuing global problem.

Thekkek N, Richards-Kortum R.

Nat Rev Cancer. 2008 Sep;8(9):725-31. doi: 10.1038/nrc2462. Review.

Supplemental Content

Support Center